UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): October 9, 2014
Aastrom Biosciences, Inc.
(Exact name of registrant as specified in its charter)
Michigan | | 000-22025 | | 94-3096597 |
(State or other jurisdiction | | (Commission | | (I.R.S. Employer |
of incorporation) | | File Number) | | Identification No.) |
24 Frank Lloyd Wright Drive, Lobby K,
Ann Arbor, Michigan | | 48105 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (734) 418-4400
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On October 9, 2014, Aastrom Biosciences, Inc. (the “Company”) issued a press release announcing plans to change its corporate name to Vericel Corporation and to move its corporate headquarters from the current location in Ann Arbor, Michigan to Cambridge, Massachusetts. The corporate name change is subject to the approval of the Company’s shareholders.
2
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 | | Press Release, dated October 9, 2014. |
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Aastrom Biosciences, Inc. |
| | |
Date: October 9, 2014 | By: | /s/ Gerard Michel |
| | Name: | Gerard Michel |
| | Title: | Chief Financial Officer, and Vice President, Corporate Development |
4
